Benitec Biopharma Inc. develops clinical-stage genetic medicines based on its proprietary Silence and Replace DNA-directed RNA interference platform. The company’s lead program, BB-301, is a silence-and-replace therapeutic in development for dysphagia in patients with Oculopharyngeal Muscular Dystrophy, or OPMD.
Company news primarily covers BB-301 clinical development, including Phase 1b/2a study updates, follow-up data from treated cohorts, safety and clinical-activity observations, and presentations at gene therapy and muscular dystrophy medical meetings. Benitec also issues periodic financial results and operational updates tied to its development-stage biotechnology business.
Benitec Biopharma (NASDAQ: BNTC) received formal FDA feedback following a Type C meeting concerning the planned BB-301 pivotal study. Discussions about an open-label, single-arm study, in which treatment is known and there is no separate comparison group, remain ongoing. The FDA requested additional available data, including information from the Benitec-sponsored OPMD Natural History Study.
The FDA agreed to a review timeline that would allow final study design confirmation in 1Q 2027. Benitec expects patient enrollment to begin in mid-2027 and plans to provide the requested data in the coming weeks. BB-301 is being developed for OPMD-related swallowing difficulties. Interim Phase 1b/2a results will be presented at ESGCT in Hamburg, October 27–30, 2026, covering 12-month follow-up for all six Cohort 1 patients and interim follow-up for all three Cohort 2 patients.
Benitec Biopharma (BNTC) reported full-year 2026 results and clinical, regulatory and cash updates for lead OPMD gene therapy BB-301.
All six patients in Cohort 1 (low dose BB-301) completed 12-month follow-up, and Cohort 2 (high dose) is fully enrolled with three patients safely treated. Clinically meaningful improvements with a favorable safety profile were seen in patient-reported and X‑ray–based swallowing measures. A Type C FDA meeting on pivotal study design was held in 3Q2026, with minutes expected in October, and interim Phase 1b/2a data will be presented at the ESGCT Congress on October 27‑30, 2026. Benitec plans to initiate a pivotal BB‑301 trial in mid‑2027.
Total operating expenses rose to $51.2 million from $41.8 million, driving a net loss of $45.5 million ($0.98 per share). Cash and cash equivalents were $180.0 million as of June 30, 2026.
Benitec Biopharma (NASDAQ:BNTC) reported Q3 2026 results and BB-301 updates. Total expenses were $13.6M vs. $15.3M a year ago, with net loss $11.9M ($0.24/share) vs. $14.5M. Cash was $184.8M, expected to fund BB-301 through its pivotal study.
BB-301 Phase 1b/2a data showed durable low-dose responses up to 24 months, deep disease-modifying efficacy at high dose, and no treatment-related severe adverse events. Cohort 2 enrollment is progressing, with updated interim data and an FDA pivotal-study design meeting expected in 2H 2026.
Benitec Biopharma (NASDAQ: BNTC) announced acceptance of interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study for Oculopharyngeal Muscular Dystrophy (OPMD) for an oral presentation at ASGCT 2026.
Data include 12-month follow-up for the first four Cohort 1 completers, a 24-month follow-up for the first Cohort 1 patient, and interim results for the first Cohort 2 patient; presentation is on 05/15/2026 09:15 AM in Boston.
Seaport Therapeutics appointed Dr. Sharon Mates to its Board of Directors on April 27, 2026. Dr. Mates co-founded and led Intra-Cellular Therapies through commercialization of CAPLYTA® and its 2025 acquisition by Johnson & Johnson for approximately $14.6 billion. CAPLYTA generated > $1.5 billion in sales prior to that acquisition. Dr. Mates currently serves on the boards of Medincell and Benitec (Nasdaq: BNTC) and will advise Seaport’s neuropsychiatry programs and governance.
Seaport Therapeutics (BNTC) appointed Dr. Sharon Mates to its Board of Directors on April 27, 2026. Dr. Mates co-founded Intra-Cellular Therapies, led commercialization of CAPLYTA and guided the company to a $14.6 billion acquisition by Johnson & Johnson in 2025. She brings FDA approval experience, board governance roles at Medincell and Benitec (Nasdaq: BNTC), and decades in neuropsychiatry drug development to support Seaport’s programs targeting depression, anxiety, and other neuropsychiatric disorders.
Benitec Biopharma (NASDAQ: BNTC) will host an Industry Forum Breakfast on March 10, 2026 at the MDA Clinical and Scientific Conference to present updated clinical results for BB-301, the only clinical-stage therapeutic in development for Oculopharyngeal Muscular Dystrophy (OPMD).
Benitec CEO Jerel A. Banks, M.D., Ph.D., will detail reported, durable improvements in dysphagia symptom burden and swallowing function observed in patients treated with low and high doses of BB-301. The session is open to registered conference attendees and virtually registered participants via MDA live stream.
Benitec Biopharma (NASDAQ: BNTC) reported positive interim Phase 1b/2a results for BB-301 in Oculopharyngeal Muscular Dystrophy (OPMD) with dysphagia. High dose BB-301 showed larger, faster improvements versus low dose at 3 months, including ~68% SSQ reduction and multi-metric radiographic gains. Low dose responses persisted and deepened at 12–24 months. No treatment-related SAEs reported for the first high-dose patient. Results presented as a late-breaking poster at the 2026 MDA Clinical & Scientific Conference.
Benitec Biopharma (NASDAQ: BNTC) announced acceptance of a late-breaking poster for the BB-301 Phase 1b/2a treatment study in oculopharyngeal muscular dystrophy (OPMD) at the Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026.
The poster (501 LB) will report interim clinical results including 12-month follow-up for four Cohort 1 completers, 24-month results for the first Cohort 1 patient, and interim data for the first Cohort 2 patient, with multiple poster session times listed.
Benitec Biopharma (NASDAQ: BNTC) reported Q2 FY2026 results and clinical progress for BB-301 for OPMD-related dysphagia.
All four Cohort 1 completers were formal responders at 12 months; Patient 1 showed deepening benefit at 24 months. Cohort 2 interim update and an FDA meeting on pivotal design are planned mid-2026. Cash was $189.0M at Dec 31, 2025; net loss was $11.8M (−$0.26/sh).